Nineteen pharmaceutical companies made the top 500 in 2020, with four in the top 100.

Pharmaceutical Network Industry Dynamics, July 27, 2020 Fortune China 500 list released, 19 pharmaceutical companies on the list.is understood that the Fortune China 500 over the years focuses on the performance and achievements of large Chinese listed companies around the world in the past year.data show that the total operating income of the 500 listed Chinese companies on the list this year reached Rmb50,500bn, up 11 per cent on last year, and net profits reached Rmb4,200bn, up more than 16 per cent from last year.the author combed the list and found that in 2020, "Fortune" list of 13 pharmaceutical companies ranked up, 5 have declined., Hengrui Pharmaceuticals rose from 470 last year to 393 this year, a big increase in the ranking.on the decline of enterprises, the five are China Resources Pharmaceuticals, Haiwang Bio, Ruikang Pharmaceuticals, Yunnan White Medicine and Tianshili., the decline of Ruikang Pharmaceuticals was larger, from 261 to 275, and was also the few loss-making enterprises among the top 500 enterprises (-927.8 million yuan).it is worth mentioning that the list of China Pharmaceutical Holdings, Shanghai Pharmaceuticals, China Resources Pharmaceuticals, Kyushu Tong ranked within 100.Also ranked 22nd on the list with revenues of 425.273 billion yuan, up three places from last year and ahead of Tencent (25th).below are the top 4 pharmaceutical companies in the pharmaceutical industry in terms of revenue in 2019.State Pharmaceutical Holdings Ranking: 22Operating Income: 425.273 (RMB100 million) In 2019, State Pharmaceutical Holdings realized operating income of RMB425.273 billion, an increase of 23.44 percent YoY, and the Group realized a profit of RMB10.620 billion, up 12.93 percent YoY., the report also shows that In addition, Sinapharmaceutical Holdings will continue to strengthen the Group's diversified business layout, focus on the development of one-stop, integrated supply chain service capabilities, and promote win-win development with upstream manufacturing and downstream end customers.will also screen suitable merger and acquisition targets in areas such as pharmaceutical retailing and medical devices to promote the overall optimization and improvement of the company's business through endogenous and extended growth "two-wheel drive" and to do its utmost to reduce the negative impact of industry policies.Shanghai Pharma Ranking: 57 Operating Income: 186.57 billion yuan (rmb100 million) Shanghai Pharma's main business in 2019 realized revenue of RMB186.57 billion, up 17.3% YoY., the pharmaceutical industry was RMB23.49 billion, up 20.7% YoY. pharmaceutical business was RMB163.08 billion, up 16.8% YoY. the reporting period, the number of its over-100 products has increased from 31 in 2018 to 35, of which more than 500 million have grown to nine, mainly in the cardiovascular, systemic anti-infection, immunomodulation, blood and hematopoietic organs. China Resources Pharmaceuticals Ranking: 60 sales of 180.2 million yuan (rmb100 million) China Resources Pharmaceuticals 2019 performance report shows that its total annual income reached HK$204,453.9 million, compared to the total income of HK$189,689.1 million in 2018 Increased by 7.8% (in RMB terms, the Group's total revenue increased by 12.6% over the same period last year), and realized gross profit of HK$34,017.7 million, a decrease of 2.6% from the 2018 gross profit of HK$34,930.4 million (up 1.7% year-on-year in RMB). the main reasons for the change in 2019 results, China Resources Pharma believes that it is mainly affected by its Dong'a Gum reduction in channel inventory in 2019, a sharp decline in performance, profit-to-loss, and goodwill impairments made during the Group's reporting period totalling HK$722.6 million. Kyushu Tong Ranking: 100 operating income: 99.497 (RMB100 million) Kyushu Tong 2019 revenue of 99.497 billion, up 14.19 percent Year-on-year, net profit of 1.727 billion, up 28.79 percent YoY, revenue and net profit both achieved steady growth, performance was bright. in fact, as an important link connecting upstream pharmaceutical production enterprises and downstream medical institutions and retail terminals, with the in-depth reform of China's pharmaceutical circulation system, increased medical and health input and the establishment of a basic guarantee system covering urban and rural residents, Kyushu Tong has achieved double growth of social and economic benefits by virtue of its large-scale, professional and modern logistics and distribution system. its first quarter 2020 report shows that its operating income was 27.173 billion yuan, up 10.18% YoY, with a solid momentum of development. .